Influenza, Human
Conditions
Keywords
Influenza, Safety, Reactogenicity, Immunogenicity, mRNA vaccine, Healthy younger adults, Healthy older adults
Brief summary
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
Interventions
BIOLOGICALF2C22C/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2B22A/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2B22B/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2B22C/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2B22D/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2B22E/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2F22A/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2F22B/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2F22C/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2F22D/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2F22E/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
COMBINATION_PRODUCTControl 1
Control vaccine was administered intramuscularly in Phase 1, at Day 1.
BIOLOGICALF2F23D/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
BIOLOGICALF2F23A/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
BIOLOGICALF2F23B/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
COMBINATION_PRODUCTControl 2
Control vaccine was administered intramuscularly in Phase 2, at Day 1.
BIOLOGICALF2F23C/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
COMBINATION_PRODUCTControl 3
Control vaccine was administered intramuscularly in Phase 2, at Day 1.
BIOLOGICALF2F22F/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
Sponsors
CureVac
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Phase 2 of this study will be observer blind.
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* A male or female between and including 18 and 50 years of age in Phase 1 and between and including 18 and 85 years of age (YA: 18-64; OA: 65-85) in Phase 2 at the time of the study intervention administration. * Healthy participants or medically stable participants as established by medical history, clinical examination, and safety laboratory assessments. Participants with chronic medical conditions with or without specific treatment are allowed to participate in this study if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrollment. * Body mass index (BMI) \>=18 kilograms per meter square (kg/m\^2) and less than or equal to (\<=) 35 kg/m\^2. * Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the participant prior to performing any study-specific procedure. * Female participants of non-childbearing potential may be enrolled in the study. * Female participants of childbearing potential may be enrolled in the study if the participant: * has practiced adequate contraception for 28 days prior to study intervention administration, and * has a negative pregnancy test on the day of study intervention administration, and * has agreed to continue adequate contraception for at least 1 month after study intervention administration
Exclusion criteria
Medical conditions * Only in Phase 1: Any clinically significant\* hematological, biochemical, urinalysis or (hemoglobin A1c) HbA1c laboratory abnormality. \*The investigator should use the clinical judgment to decide which abnormalities are clinically significant. * Participant tested positive for influenza by local health authority-approved testing methods within 180 days prior to Day 1. * Current or past malignancy, unless completely resolved without clinically significant sequelae for \>5 years. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection, based on medical history and physical examination (no laboratory testing required). However, in Phase 2, HIV-infected individuals may be enrolled if participants have been stable on antiretroviral therapy for the past 6 consecutive months, i.e., their treatment has not been modified, their cluster of differentiation 4 (CD4) cell count is \>=200/cubic millimeter (mm\^3) and their viral load has been undetectable (i.e., HIV-RNA less than (\<) 50 copies/milliliter \[mL\]) (based on medical records, no laboratory testing required). * History of myocarditis or pericarditis less than or equal to 10 years prior to vaccine administration, including a history of myocarditis or pericarditis following vaccination with an mRNA coronavirus disease 2019 (COVID-19) vaccine. * Participants with history of hypersensitivity or severe allergic reaction to any previous vaccine or hypersensitivity likely to be exacerbated by any component of the study intervention (including latex, polyethylene glycol, egg protein and aminoglycoside antibiotics). * History of, or uncontrolled neurological disorders or seizures, including Guillain-Barré syndrome and Bell's palsy, with the exception of febrile seizures during childhood. * Any history of dementia or any medical condition that moderately or severely impairs cognition. * Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe. * Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. Prior/Concomitant therapy * Administration of an influenza vaccine (including any of the study investigational vaccines) within 180 days before enrollment or planned administration within 28 days (Day 29) after the study intervention administration. * Phase 1: Administration of a vaccine not foreseen by the study protocol in the period starting 28 days (Day -28) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration. Phase 2: Administration of a vaccine not foreseen by the study protocol in the period starting 15 days (Day -15) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration. \*In case emergency mass vaccination for an unforeseen public health threat is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced to 7 days if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly. * Use of any investigational or non-registered product (drug, vaccine, or invasive medical device) other than the study intervention during the period beginning 30 days before the study intervention administration, or their planned use during the study period. * Administration of long-acting immune-modifying drugs within 90 days before enrollment or planned use at any time during the study period. * Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration, or planned administration during the study period. Administration of monoclonal antibodies specifically directed against the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), for treatment of COVID-19 disease is allowed. * Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the study intervention administration. For corticosteroids, this will mean prednisone equivalent \>=20 milligrams (mg)/day. Inhaled, topical and intraarticular steroids are allowed. Other exclusions * Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). * Pregnant or lactating female. * Bedridden participants. * Female planning to become pregnant or planning to discontinue contraceptive precautions within the 1-month post-dosing period. * Alcoholism or substance use disorder within the past 24 months based on the presence of 2 or more of the following abuse criteria: hazardous use, social/interpersonal problems related to use, neglect of major roles to use, withdrawal, tolerance, use of larger amounts or longer, repeated attempts to quit or control use, much time spent using, physical or psychological problems related to use, activities given up to use, craving. * Any study personnel or their immediate dependents, family, or household members. * Participants with extensive tattoos covering deltoid region on both arms that would preclude the assessment of local reactogenicity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Antigen 2 Antibody SCR | From Day 1 to Day 29 | — |
| Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | From Day 1 (baseline) to Day 29 | GMI is defined as the geometric mean of the ratios of the post dosing titer over the Day 1 titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | From Day 1 to Day 29 | SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer \>= 1:40 or a pre-dose anti-vaccine antibody titer \>= 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | At Day 1 | SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer \>= 1:40. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Percentage of Participants With Antigen 1 Antibody SPR | At Day 29 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| GMT of Antigen 2 Antibody Titer | At Day 29 | — |
| GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | From Day 1 (baseline) to Day 29 | — |
| Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Day 1 to Day 7 | Assessed solicited administration site events included pain, redness (Erythema), swelling, lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. |
| Number of Participants Reporting Any Solicited Systemic AEs | Day 1 to Day 7 | Assessed solicited systemic events included fever (defined as axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F), chills, headache, fatigue, myalgia, and arthralgia. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. |
| Number of Participants Reporting Any Unsolicited AEs | Day 1 to Day 28 | An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence the event regardless of intensity grade or relation to the study vaccination. |
| Number of Participants Reporting Serious Adverse Events (SAEs) | Day 1 to Day 183 | An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product. Any = occurrence the event regardless of intensity grade or relation to the study vaccination. |
| Number of Participants Reporting AEs of Special Interest (AESIs) | Day 1 to Day 183 | The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs). Any = occurrence the event regardless of intensity grade or relation to the study vaccination. |
| Number of Participants Reporting Medically Attended Events (MAEs) | Day 1 to Day 183 | MAE is defined as an AE that results in an unscheduled visit to a medical professional (e.g., physician's office visits, emergency room visits or hospitalization). Any = occurrence the event regardless of intensity grade or relation to the study vaccination. |
| Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | At Day 8 compared to baseline (Day 1) | Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline. |
| Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | At Day 29 compared to baseline (Day 1) | Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline. |
| Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | At Day 29 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | From Day 1 (baseline) to Day 92 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | From Day 1 (baseline) to Day 183 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Percentage of Participants With Antigen 1 Antibody SPR | At Day 183 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| GMT of Antigen 2 Antibody Titer | At Day 92 and Day 183 | — |
| GMI of Antigen 2 Antibody Titer | From Day 1 to Day 92 and Day 1 to Day 183 | — |
| GMT of Antigen 1 Antibody Titer | At Day 92 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
Countries
Belgium, Canada, South Africa, United States
Participant flow
Pre-assignment details
A total of 1275 participants were included in Enrolled set, out of which only 1256 were included in Exposed set and started the study.
Participants by arm
| Arm | Count |
|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group YA Participants received a single dose of Flu mRNA study intervention F2C22C/DL001Z (GSKVx000000039714) administered in Phase 1, at Day 1. | 21 |
| Flu mRNA_Ph1_2 YA Group YA participants received a single dose of Flu mRNA study intervention F2B22A/DL001Z (GSKVx000000040038) administered in Phase 1, at Day 1. | 22 |
| Flu mRNA_Ph1_3 YA Group YA participants received a single dose of Flu mRNA study intervention F2B22B/DL001Z (GSKVx000000040668) administered in Phase 1, at Day 1. | 23 |
| Flu mRNA_Ph1_4 YA Group YA participants received a single dose of Flu mRNA study intervention F2B22C/DL001Z (GSKVx000000040671) administered in Phase 1, at Day 1. | 23 |
| Flu mRNA_Ph1_5 YA Group YA participants received a single dose of Flu mRNA study intervention F2B22D/DL001Z (GSKVx000000040674) administered in Phase 1, at Day 1. | 22 |
| Flu mRNA_Ph1_6 YA Group YA participants received a single dose of Flu mRNA study intervention F2B22E/DL001Z (GSKVx000000040677) administered in Phase 1, at Day 1. | 25 |
| Flu mRNA_Ph1_7 YA Group YA participants received a single dose of Flu mRNA study intervention F2F22A/DL001Z (GSKVx000000040641) administered in Phase 1, at Day 1. | 23 |
| Flu mRNA_Ph1_8 YA Group YA participants received a single dose of Flu mRNA study intervention F2F22B/DL001Z (GSKVx000000040644) administered in Phase 1, at Day 1. | 22 |
| Flu mRNA_Ph1_9 YA Group YA participants received a single dose of Flu mRNA (GSK4382276A) study intervention F2F22C/DL001Z (GSKVx000000040647) administered in Phase 1, at Day 1. | 23 |
| Flu mRNA_Ph1_10 YA Group YA participants received a single dose of Flu mRNA study intervention F2F22D/DL001Z (GSKVx000000040650) administered in Phase 1, at Day 1. | 22 |
| Flu mRNA_Ph1_11 YA Group YA participants received a single dose of Flu mRNA study intervention F2F22E/DL001Z (GSKVx000000040996) administered in Phase 1, at Day 1. | 23 |
| Flu mRNA_Ph1_12 YA Group YA participants received a single dose of Flu mRNA study intervention F2F22F/DL001Z (GSKVx000000040999) administered in Phase 1, at Day 1. | 21 |
| Control Ph1_YA Group YA participants received a single dose of Control 1 administered in Phase 1, at Day 1. | 23 |
| Flu mRNA_Ph2_1_YA Group YA participants received a single dose of Flu mRNA study intervention F2F23D/DL001Z-NH administered in Phase 2, at Day 1. | 115 |
| Flu mRNA_Ph2_2_YA Group YA participants received a single dose of Flu mRNA study intervention F2F23A/DL001Z-NH administered in Phase 2, at Day 1 | 108 |
| Flu mRNA_Ph2_3_YA Group YA participants received a single dose of Flu mRNA study intervention F2F23B/DL001Z-NH administered in Phase 2, at Day 1. | 137 |
| Control_Ph2_YA Group YA participants received single dose of Control 2 vaccine administered in Phase 2, at Day 1. | 120 |
| Flu mRNA_Ph2_1_Older Adults (OA) Group OA participants received a single dose of Flu mRNA study intervention F2F23A/DL001Z-NH administered in Phase 2, at Day 1. | 119 |
| Flu mRNA_Ph2_2_OA Group OA participants received a single dose of Flu mRNA study intervention F2F23B/DL001Z-NH administered in Phase 2, at Day 1. | 122 |
| Flu mRNA_Ph2_3_OA Group OA participants received a single dose of Flu mRNA study intervention F2F23C/DL001Z-NH administered in Phase 2, at Day 1. | 125 |
| Control_Ph2_OA Group OA participants received a single dose of Control 3 vaccine administered in Phase 2, at Day 1. | 117 |
| Total | 1,256 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 | FG015 | FG016 | FG017 | FG018 | FG019 | FG020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 3 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 2 | 0 |
| Overall Study | MIGRATED / MOVED FROM THE STUDY AREA | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Other | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 1 | 2 | 0 | 2 | 3 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 2 | 2 | 0 | 1 |
Baseline characteristics
| Characteristic | Flu mRNA_Ph1_11 YA Group | Flu mRNA_Ph1_3 YA Group | Flu mRNA_Ph1_4 YA Group | Flu mRNA_Ph1_5 YA Group | Flu mRNA_Ph1_6 YA Group | Flu mRNA_Ph1_7 YA Group | Flu mRNA_Ph1_8 YA Group | Flu mRNA_Ph1_9 YA Group | Flu mRNA_Ph1_10 YA Group | Flu mRNA_Ph1_2 YA Group | Flu mRNA_Ph1_1 Younger Adults (YA) Group | Flu mRNA_Ph1_12 YA Group | Control Ph1_YA Group | Flu mRNA_Ph2_1_YA Group | Flu mRNA_Ph2_2_YA Group | Flu mRNA_Ph2_3_YA Group | Control_Ph2_YA Group | Flu mRNA_Ph2_1_Older Adults (OA) Group | Flu mRNA_Ph2_2_OA Group | Flu mRNA_Ph2_3_OA Group | Control_Ph2_OA Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized 18 - 64 years | 23 Participants | 23 Participants | 23 Participants | 22 Participants | 25 Participants | 23 Participants | 22 Participants | 23 Participants | 22 Participants | 22 Participants | 21 Participants | 21 Participants | 23 Participants | 114 Participants | 108 Participants | 137 Participants | 120 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 773 Participants |
| Age, Customized 65 - 84 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 118 Participants | 121 Participants | 124 Participants | 117 Participants | 481 Participants |
| Age, Customized ≥ 85 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized All other Races | 6 Participants | 4 Participants | 5 Participants | 6 Participants | 6 Participants | 7 Participants | 3 Participants | 6 Participants | 7 Participants | 2 Participants | 5 Participants | 8 Participants | 4 Participants | 19 Participants | 15 Participants | 19 Participants | 17 Participants | 25 Participants | 22 Participants | 19 Participants | 21 Participants | 226 Participants |
| Race/Ethnicity, Customized MULTIPLE | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 9 Participants |
| Race/Ethnicity, Customized NOT REPORTED | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants | 3 Participants | 5 Participants | 4 Participants | 5 Participants | 8 Participants | 31 Participants |
| Race/Ethnicity, Customized UNKNOWN | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized WHITE | 17 Participants | 19 Participants | 18 Participants | 16 Participants | 18 Participants | 16 Participants | 19 Participants | 17 Participants | 15 Participants | 19 Participants | 14 Participants | 13 Participants | 19 Participants | 94 Participants | 91 Participants | 116 Participants | 96 Participants | 88 Participants | 95 Participants | 101 Participants | 87 Participants | 988 Participants |
| Sex: Female, Male Female | 12 Participants | 15 Participants | 13 Participants | 13 Participants | 13 Participants | 11 Participants | 13 Participants | 13 Participants | 11 Participants | 11 Participants | 12 Participants | 13 Participants | 8 Participants | 65 Participants | 55 Participants | 86 Participants | 70 Participants | 69 Participants | 55 Participants | 61 Participants | 71 Participants | 690 Participants |
| Sex: Female, Male Male | 11 Participants | 8 Participants | 10 Participants | 9 Participants | 12 Participants | 12 Participants | 9 Participants | 10 Participants | 11 Participants | 11 Participants | 9 Participants | 8 Participants | 15 Participants | 50 Participants | 53 Participants | 51 Participants | 50 Participants | 50 Participants | 67 Participants | 64 Participants | 46 Participants | 566 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk | EG016 affected / at risk | EG017 affected / at risk | EG018 affected / at risk | EG019 affected / at risk | EG020 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 22 | 0 / 23 | 0 / 23 | 0 / 22 | 0 / 25 | 0 / 23 | 0 / 22 | 0 / 23 | 0 / 22 | 0 / 23 | 0 / 21 | 0 / 23 | 0 / 115 | 0 / 108 | 0 / 137 | 0 / 120 | 0 / 119 | 0 / 122 | 0 / 125 | 0 / 117 |
| other Total, other adverse events | 16 / 21 | 22 / 22 | 23 / 23 | 22 / 23 | 20 / 22 | 24 / 25 | 22 / 23 | 20 / 22 | 19 / 23 | 20 / 22 | 23 / 23 | 19 / 21 | 18 / 23 | 99 / 115 | 95 / 108 | 127 / 137 | 89 / 120 | 83 / 119 | 88 / 122 | 91 / 125 | 69 / 117 |
| serious Total, serious adverse events | 0 / 21 | 0 / 22 | 0 / 23 | 0 / 23 | 0 / 22 | 1 / 25 | 0 / 23 | 0 / 22 | 0 / 23 | 0 / 22 | 0 / 23 | 1 / 21 | 0 / 23 | 0 / 115 | 1 / 108 | 0 / 137 | 3 / 120 | 3 / 119 | 6 / 122 | 2 / 125 | 2 / 117 |
Outcome results
Primary
Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29
GMI is defined as the geometric mean of the ratios of the post dosing titer over the Day 1 titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: From Day 1 (baseline) to Day 29
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 1.09 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 12.83 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 1.32 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 0.93 Ratio |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.87 Ratio |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 3.13 Ratio |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 11.41 Ratio |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 9.16 Ratio |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 6.77 Ratio |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 7.61 Ratio |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.92 Ratio |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.43 Ratio |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 12.08 Ratio |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 9.81 Ratio |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 3.30 Ratio |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 2.09 Ratio |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 10.39 Ratio |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.99 Ratio |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 7.39 Ratio |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 3.36 Ratio |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.87 Ratio |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 3.13 Ratio |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 9.06 Ratio |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 8.26 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 3.18 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.54 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 9.54 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 6.33 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 7.38 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.43 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 4.62 Ratio |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 1.64 Ratio |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.58 Ratio |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 8.21 Ratio |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.89 Ratio |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 8.86 Ratio |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 9.26 Ratio |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 11.20 Ratio |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 14.87 Ratio |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.66 Ratio |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.83 Ratio |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 10.12 Ratio |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.73 Ratio |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.80 Ratio |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 8.39 Ratio |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 8.42 Ratio |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 11.38 Ratio |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.42 Ratio |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.89 Ratio |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.27 Ratio |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 7.44 Ratio |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 9.32 Ratio |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 2.01 Ratio |
| Control Ph1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 2.60 Ratio |
| Control Ph1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 3.47 Ratio |
| Control Ph1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 3.20 Ratio |
| Control Ph1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 6.14 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.04 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 5.36 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.83 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 3.75 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 6.42 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 1.40 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 6.92 Ratio |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 1.72 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 1.90 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 4.04 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 5.32 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 2.16 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.33 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 1.54 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 7.96 Ratio |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 7.89 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 10.09 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 9.51 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 5.96 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 5.32 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 1.73 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 2.36 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.31 Ratio |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 2.07 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 2.46 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 4.13 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 3.08 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 3.58 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 3.76 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 2.05 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 5.92 Ratio |
| Control_Ph2_YA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 2.27 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 6.34 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.40 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 1.39 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 3.24 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 8.35 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 4.20 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.77 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 2.51 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 2.36 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 1.38 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.89 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 3.18 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 8.41 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 4.72 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.71 Ratio |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 8.59 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 2.43 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 2.89 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 1.47 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 1.98 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 4.00 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 10.00 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 5.56 Ratio |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 9.53 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 1 | 5.99 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A1 Assay 2 | 2.90 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 1 | 3.46 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 2 | 2.55 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu A2 Assay 1 | 5.62 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 2 | 2.63 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B2 Assay 2 | 1.62 Ratio |
| Control_Ph2_OA Group | Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29 | Flu B1 Assay 1 | 3.37 Ratio |
Primary
Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer
Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: At Day 29
Population: The analysis was performed on the Per Protocol Set (PPS), which included all eligible participants who received the study intervention dose according to the protocol, had recorded anti-HI immunogenicity results pre- and post-dose, without intercurrent conditions, and did not use prohibited medications or vaccinations before Day 29 and for whom data were available for the specified analysis at the specified timepoints. Blood sample results that deviated from the analysis criteria were excluded.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 240.13 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 469.49 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 15.64 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 74.84 Titers |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 149.88 Titers |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 689.10 Titers |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 135.68 Titers |
| Flu mRNA_Ph1_2 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 335.19 Titers |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 247.82 Titers |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 90.47 Titers |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 154.29 Titers |
| Flu mRNA_Ph1_3 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 536.73 Titers |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 143.63 Titers |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 359.26 Titers |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 727.48 Titers |
| Flu mRNA_Ph1_4 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 168.29 Titers |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 380.39 Titers |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 160.05 Titers |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 87.87 Titers |
| Flu mRNA_Ph1_5 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 739.83 Titers |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 150.39 Titers |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 689.88 Titers |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 331.81 Titers |
| Flu mRNA_Ph1_6 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 98.27 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 45.65 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 123.35 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 349.06 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 103.70 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 87.80 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 536.57 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 295.42 Titers |
| Flu mRNA_Ph1_7 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 190.37 Titers |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 568.51 Titers |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 97.63 Titers |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 151.48 Titers |
| Flu mRNA_Ph1_8 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 324.35 Titers |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 110.15 Titers |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 409.93 Titers |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 1545.64 Titers |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 133.43 Titers |
| Flu mRNA_Ph1_9 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 624.12 Titers |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 370.39 Titers |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 139.36 Titers |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 617.81 Titers |
| Flu mRNA_Ph1_10 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 99.75 Titers |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 308.20 Titers |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 135.41 Titers |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 534.31 Titers |
| Flu mRNA_Ph1_11 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 151.53 Titers |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 501.11 Titers |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 88.55 Titers |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 341.20 Titers |
| Flu mRNA_Ph1_12 YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 161.25 Titers |
| Control Ph1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 208.78 Titers |
| Control Ph1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 764.90 Titers |
| Control Ph1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 38.02 Titers |
| Control Ph1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 224.76 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 605.48 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 262.86 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 97.37 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 436.01 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 50.99 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 277.45 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 98.57 Titers |
| Flu mRNA_Ph2_1_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 370.16 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 409.56 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 469.09 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 260.70 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 114.95 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 692.40 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 305.19 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 113.45 Titers |
| Flu mRNA_Ph2_2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 62.65 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 143.74 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 75.46 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 292.27 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 617.79 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 341.88 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 125.81 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 687.04 Titers |
| Flu mRNA_Ph2_3_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 446.20 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 487.32 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 58.80 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 913.91 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 175.58 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 200.28 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 440.96 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 46.97 Titers |
| Control_Ph2_YA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 264.10 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 59.83 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 516.25 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 283.03 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 505.46 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 159.66 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 255.17 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 173.94 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 565.86 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 532.34 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 281.44 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 184.85 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 495.42 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 160.93 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 287.14 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 583.05 Titers |
| Flu mRNA_Ph2_2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 81.06 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 546.58 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 621.87 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 299.04 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 193.96 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 624.06 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 191.29 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 338.20 Titers |
| Flu mRNA_Ph2_3_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 90.00 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 56.52 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A1 Assay 2 | 176.21 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 744.28 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 2 | 397.32 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 107.50 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 258.03 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B2 Assay 2 | 329.89 Titers |
| Control_Ph2_OA Group | Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 760.08 Titers |
Primary
GMI of Antigen 2 Antibody Titer From Day 1 to Day 29
Time frame: From Day 1 (baseline) to Day 29
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 4.82 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 6.99 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 4.00 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 4.82 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 6.34 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 4.98 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 5.12 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 6.85 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 6.04 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 5.46 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 5.18 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 3.86 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 6.17 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 5.40 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 7.30 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 4.44 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 5.03 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 4.71 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 4.91 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 6.65 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 5.82 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 6.02 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 7.98 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 6.14 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 2.17 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 1.41 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 2.68 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 2.99 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 3.25 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 3.54 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 3.72 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 6.37 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 4.17 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 4.16 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 7.84 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 3.84 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 4.57 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 4.47 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 4.54 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 8.24 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 1.27 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 1.54 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 1.81 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 2.26 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 3.57 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 3.34 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 6.06 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 3.05 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 3.22 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 3.83 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 5.86 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 3.49 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 4.09 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 4.45 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 8.13 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 4.00 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B2 | 2.10 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A1 | 1.36 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu A2 | 1.52 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer From Day 1 to Day 29 | Flu B1 | 2.05 Ratio |
Primary
GMT of Antigen 2 Antibody Titer
Time frame: At Day 29
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 2566.54 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 5588.80 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 782.28 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 1494.07 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 974.11 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 3373.58 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 4087.84 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 2122.26 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 1693.64 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 4140.51 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 3214.91 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 755.19 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 5830.63 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 3281.89 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 1673.20 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 868.89 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 984.15 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 1459.78 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 2614.82 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 5311.18 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 1903.93 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 6374.69 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 1137.13 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 3204.51 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 1126.63 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 1424.37 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 424.76 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 926.76 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 2600.03 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 763.90 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 778.89 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 591.78 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 2911.06 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 920.46 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 696.93 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 940.60 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 763.06 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 3171.75 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 1070.07 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 988.40 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 376.75 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 151.87 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 369.35 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 1267.32 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 1107.49 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 719.59 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 3405.35 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 863.96 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 1156.39 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 759.26 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 835.61 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 3653.30 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 941.93 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 1355.41 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 4243.16 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 1159.00 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2 | 504.28 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1 | 483.95 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2 | 1999.75 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1 | 194.60 Titers |
Primary
Number of Participants Reporting AEs of Special Interest (AESIs)
The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs). Any = occurrence the event regardless of intensity grade or relation to the study vaccination.
Time frame: Day 1 to Day 183
Population: The analysis was performed on the ES, which included all participants who received a study intervention and for whom AESI data were available at specified timepoints.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 1 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Control Ph1_YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 1 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 1 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 1 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting AEs of Special Interest (AESIs) | 0 Participants |
Primary
Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs)
Assessed solicited administration site events included pain, redness (Erythema), swelling, lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Time frame: Day 1 to Day 7
Population: The analysis was performed on the Exposed Set (ES), which included all participants who received a study intervention and for whom solicited administration site events data were available at specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 0 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 0 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 15 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 6 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 19 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 2 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 1 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 10 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 8 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 0 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 2 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 21 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 2 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 10 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 1 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 20 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 3 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 10 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 1 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 19 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 4 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 14 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 22 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 2 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 1 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 1 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 5 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 15 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 1 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 9 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 19 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 2 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 3 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 8 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 18 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 1 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 0 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 3 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 10 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 19 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 8 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 3 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 21 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 3 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 11 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 3 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 18 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 3 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 2 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 2 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 13 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 2 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 3 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 28 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 82 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 3 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 5 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 86 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 41 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 7 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 118 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 53 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 7 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 8 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 1 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 1 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 53 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 14 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 6 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 6 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 63 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 20 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 19 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 64 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 6 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 5 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 9 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 78 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 14 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 8 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Lymphadenopathy | 10 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Pain | 41 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Erythema | 4 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Swelling | 6 Participants |
Primary
Number of Participants Reporting Any Solicited Systemic AEs
Assessed solicited systemic events included fever (defined as axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F), chills, headache, fatigue, myalgia, and arthralgia. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Time frame: Day 1 to Day 7
Population: The analysis was performed on the ES, which included all participants who received a study intervention and for whom solicited systemic events data were available at specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 3 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 11 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 10 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 4 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 10 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 1 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 2 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 21 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 12 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 19 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 17 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 12 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 8 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 6 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 15 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 15 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 11 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 17 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 14 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 10 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 17 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 18 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 18 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 10 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 16 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 15 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 4 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 10 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 17 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 11 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 18 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 10 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 1 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 19 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 9 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 17 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 15 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 16 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 15 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 15 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 8 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 9 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 19 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 5 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 15 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 11 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 17 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 16 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 12 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 11 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 17 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 14 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 16 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 7 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 18 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 12 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 16 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 5 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 7 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 16 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 18 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 20 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 20 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 17 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 9 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 9 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 13 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 6 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 10 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 18 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 13 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 17 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 9 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 0 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 5 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 9 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 0 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 0 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 30 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 54 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 56 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 5 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 31 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 58 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 37 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 8 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 39 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 58 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 70 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 70 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 103 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 73 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 99 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 98 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 48 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 25 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 36 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 49 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 35 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 18 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 11 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 2 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 15 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 18 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 44 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 1 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 36 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 36 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 5 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 27 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 40 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 51 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 36 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 19 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 37 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 33 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 14 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 50 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 64 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 57 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Temperature | 2 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Chills | 7 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Headache | 19 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Arthralgia | 9 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Fatigue | 26 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Solicited Systemic AEs | Myalgia | 19 Participants |
Primary
Number of Participants Reporting Any Unsolicited AEs
An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence the event regardless of intensity grade or relation to the study vaccination.
Time frame: Day 1 to Day 28
Population: The analysis was performed on the ES, which included all participants who received a study intervention and for whom unsolicited AEs data were available at specified timepoints.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Any Unsolicited AEs | 7 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Any Unsolicited AEs | 10 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Any Unsolicited AEs | 5 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Any Unsolicited AEs | 7 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Any Unsolicited AEs | 6 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Any Unsolicited AEs | 12 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Any Unsolicited AEs | 4 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Any Unsolicited AEs | 6 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Any Unsolicited AEs | 12 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Any Unsolicited AEs | 8 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Any Unsolicited AEs | 7 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Any Unsolicited AEs | 9 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Any Unsolicited AEs | 7 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Any Unsolicited AEs | 34 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Any Unsolicited AEs | 40 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Any Unsolicited AEs | 60 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Any Unsolicited AEs | 45 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Any Unsolicited AEs | 24 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Any Unsolicited AEs | 22 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Any Unsolicited AEs | 28 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Any Unsolicited AEs | 20 Participants |
Primary
Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.
Time frame: At Day 29 compared to baseline (Day 1)
Population: The analysis was performed on the ES, which included all participants who received a study intervention and for whom laboratory data were available for the specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 1 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 1 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 1 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 1 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Control Ph1_YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Control Ph1_YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
Primary
Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.
Time frame: At Day 8 compared to baseline (Day 1)
Population: The analysis was performed on the ES, which included all participants who received a study intervention and for whom laboratory data were available at specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 1 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 1 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 2 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 1 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 1 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 2 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 1 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 0 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 0 Participants |
| Control Ph1_YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Normal or missing to clinically significant | 1 Participants |
| Control Ph1_YA Group | Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical Chemistry | Abnormal non-significant to clinically significant | 1 Participants |
Primary
Number of Participants Reporting Medically Attended Events (MAEs)
MAE is defined as an AE that results in an unscheduled visit to a medical professional (e.g., physician's office visits, emergency room visits or hospitalization). Any = occurrence the event regardless of intensity grade or relation to the study vaccination.
Time frame: Day 1 to Day 183
Population: The analysis was performed on the ES, which included all participants who received a study intervention and for whom MAEs data were available at specified timepoints.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Medically Attended Events (MAEs) | 3 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 3 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 4 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 3 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 2 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 7 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 3 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 3 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 3 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 3 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 2 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 8 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 6 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 28 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 28 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 29 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 30 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Medically Attended Events (MAEs) | 20 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 21 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 17 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Medically Attended Events (MAEs) | 18 Participants |
Primary
Number of Participants Reporting Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product. Any = occurrence the event regardless of intensity grade or relation to the study vaccination.
Time frame: Day 1 to Day 183
Population: The analysis was performed on the ES, which included all participants who received a study intervention and for whom SAEs data were available at specified timepoints.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_2 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_3 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_4 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_5 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_6 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 1 Participants |
| Flu mRNA_Ph1_7 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_8 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_9 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_10 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_11 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph1_12 YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 1 Participants |
| Control Ph1_YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph2_1_YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Flu mRNA_Ph2_2_YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 1 Participants |
| Flu mRNA_Ph2_3_YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 0 Participants |
| Control_Ph2_YA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 3 Participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 3 Participants |
| Flu mRNA_Ph2_2_OA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 6 Participants |
| Flu mRNA_Ph2_3_OA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 2 Participants |
| Control_Ph2_OA Group | Number of Participants Reporting Serious Adverse Events (SAEs) | 2 Participants |
Primary
Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR)
SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer \>= 1:40 or a pre-dose anti-vaccine antibody titer \>= 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: From Day 1 to Day 29
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 0 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 78.9 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 0 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 5.3 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 36.4 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 90.9 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 13.6 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 68.2 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 22.7 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 68.2 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 59.1 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 27.3 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 87.0 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 65.2 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 52.2 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 17.4 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 47.6 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 19.0 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 71.4 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 57.1 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 79.2 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 33.3 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 70.8 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 16.7 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 26.1 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 4.3 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 60.9 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 56.5 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 73.9 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 26.1 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 65.2 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 8.7 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 18.2 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 68.2 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 13.6 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 63.6 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 68.4 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 73.7 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 84.2 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 10.5 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 31.6 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 81.0 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 19.0 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 47.6 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 90.5 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 68.2 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 77.3 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 27.3 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 18.2 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 15.8 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 47.4 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 57.9 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 16.7 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 33.3 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 54.5 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 31.8 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 59.1 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 25.7 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 60.4 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 12.9 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 49.5 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 54.5 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 12.9 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 72.3 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 17.8 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 21.6 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 49.5 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 62.9 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 20.6 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 26.0 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 12.4 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 70.1 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 63.8 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 79.3 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 67.2 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 62.8 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 63.6 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 17.4 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 19.0 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 23.1 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 24.0 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 50.0 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 21.9 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 43.9 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 37.7 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 47.4 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 38.3 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 36.5 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 32.2 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 28.7 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 49.1 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 17.6 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 17.6 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 43.5 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 51.4 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 38.0 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 62.0 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 27.6 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 52.2 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 20.0 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 22.6 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 69.0 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 59.1 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 38.8 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 63.4 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 29.6 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 53.9 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 40.9 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 17.4 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 20.9 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 71.3 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 60.9 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 64.6 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 1 | 49.5 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A1 Assay 2 | 36.0 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 1 | 39.6 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 2 | 38.7 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu A2 Assay 1 | 54.1 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B2 Assay 2 | 23.4 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 2 | 32.4 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | Flu B1 Assay 1 | 41.4 Percentage of participants |
Primary
Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR)
SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer \>= 1:40. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: At Day 1
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 60.0 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 20.0 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 85.0 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 95.5 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 95.5 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 27.3 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 63.6 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 50.0 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 22.7 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 86.4 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 13.0 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 65.2 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 95.7 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 61.9 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 76.2 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 33.3 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 91.7 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 37.5 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 8.3 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 26.1 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 95.7 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 69.6 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 34.8 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 26.1 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 78.3 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 36.4 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 95.5 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 54.5 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 33.3 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 66.7 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 81.0 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 47.6 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 76.2 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 9.5 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 45.5 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 27.3 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 95.2 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 28.6 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 47.6 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 95.0 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 85.7 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 95.5 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 27.3 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 45.5 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 97.1 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 70.6 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 78.4 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 71.6 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 13.7 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 97.1 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 18.6 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 98.0 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 78.8 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 96.0 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 71.7 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 68.7 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 98.0 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 22.2 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 8.3 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 21.6 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 7.3 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 66.4 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 77.6 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 98.4 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 62.4 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 97.6 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 96.6 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 32.8 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 99.1 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 60.3 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 63.8 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 98.3 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 9.6 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 82.8 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 13.6 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 95.5 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 96.4 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 91.8 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 38.2 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 84.5 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 83.6 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 93.6 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 94.9 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 95.7 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 81.2 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 86.3 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 30.8 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 71.8 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 98.3 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 14.9 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 99.2 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 97.5 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 95.0 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 84.9 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 82.4 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 31.9 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 65.5 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 8.6 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 1 | 16.2 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A1 Assay 2 | 88.9 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 1 | 99.1 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 2 | 88.9 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu A2 Assay 1 | 32.5 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 2 | 86.3 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B2 Assay 2 | 98.3 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | Flu B1 Assay 1 | 99.1 Percentage of participants |
Primary
Percentage of Participants With Antigen 1 Antibody SPR
Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: At Day 29
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 84.2 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 94.7 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 31.6 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 72.7 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 95.4 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 90.9 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 95.7 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 90.5 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 79.2 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.8 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 56.5 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.7 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 82.6 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 82.6 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.5 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 90.9 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 94.7 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 89.5 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 95.2 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 95.2 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.2 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.5 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 86.4 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 84.2 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 100 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.5 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 59.1 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 82.2 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 55.4 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 99.0 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 83.2 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 95.0 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 99.0 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 99.0 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 83.5 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 95.9 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 83.5 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 97.9 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 65.6 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 92.6 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 73.3 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 99.2 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 99.2 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 83.5 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 100 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 69.6 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 87.7 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 95.6 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 100 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 63.5 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 98.2 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 64.5 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 98.1 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 88.0 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 97.2 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 97.2 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 99.1 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 96.5 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 98.3 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 86.2 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 94.8 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 72.3 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 99.1 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 99.1 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 97.4 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 90.4 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 96.5 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 71.3 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 69.4 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 2 | 90.1 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 2 | 97.3 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 81.1 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 2 | 98.2 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
Primary
Percentage of Participants With Antigen 2 Antibody SCR
Time frame: From Day 1 to Day 29
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 69.6 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 39.1 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 69.6 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 73.9 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 63.6 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 77.3 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 50.0 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 63.6 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 57.9 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 57.9 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 52.6 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 63.2 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 61.9 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 76.2 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 66.7 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 57.1 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 54.5 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 86.4 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 54.5 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 54.5 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 63.2 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 78.9 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 61.1 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 63.2 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 45.5 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 18.2 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 27.3 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 9.1 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 43.6 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 68.3 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 32.7 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 38.6 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 46.4 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 77.3 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 50.5 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 49.0 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 58.3 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 50.4 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 61.2 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 77.7 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 24.3 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 5.2 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 7.0 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 3.5 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 38.9 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 39.8 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 34.3 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 58.3 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 61.2 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 44.8 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 35.3 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 40.5 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 72.2 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 45.2 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 48.7 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 51.3 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A2 | 6.3 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B2 | 13.5 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu B1 | 18.9 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 2 Antibody SCR | Flu A1 | 5.4 Percentage of participants |
Secondary
GMI of Antigen 1 Antibody Titer From Day 1 to Day 183
Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: From Day 1 (baseline) to Day 183
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 1.06 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.31 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.55 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 1.50 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.34 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 3.49 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 1.96 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.39 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.87 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 1.91 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.01 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 1.77 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.82 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 2.04 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.47 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.04 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 1.74 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.83 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.25 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 1.75 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 1.80 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.03 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.75 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 3.39 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.87 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 1.99 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.72 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.03 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.99 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 3.01 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 2.57 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.94 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 2.05 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.88 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.70 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.21 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 2.42 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.33 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.02 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.51 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 2.09 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.02 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.53 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 2.02 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 2.11 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.94 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.33 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.22 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.26 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 3.58 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 1.10 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 2 | 2.59 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.16 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.23 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 1.58 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.85 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 3.22 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 1.75 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.38 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.84 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 3.17 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 1.70 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.41 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 4.34 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.07 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.15 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 2.02 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.56 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.99 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.34 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 3.20 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 2.02 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.51 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 3.37 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 4.00 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 1.89 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 4.28 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 2.09 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 3.32 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.56 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B2 Assay 1 | 1.82 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu B1 Assay 1 | 2.49 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A1 Assay 1 | 2.96 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 183 | Flu A2 Assay 1 | 2.29 Ratio |
Secondary
GMI of Antigen 1 Antibody Titer From Day 1 to Day 92
Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: From Day 1 (baseline) to Day 92
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 1.27 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 1.00 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 6.95 Ratio |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 0.98 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 5.38 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 4.68 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.25 Ratio |
| Flu mRNA_Ph1_2 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.23 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.05 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 3.96 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 2.54 Ratio |
| Flu mRNA_Ph1_3 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 1.72 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 4.64 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.75 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.09 Ratio |
| Flu mRNA_Ph1_4 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.33 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.41 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 2.49 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 5.05 Ratio |
| Flu mRNA_Ph1_5 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.52 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.52 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 1.95 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.08 Ratio |
| Flu mRNA_Ph1_6 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 5.11 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 3.35 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.53 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 1.91 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 1.82 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 5.05 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.44 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 3.76 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.46 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 3.67 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 5.30 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.30 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.18 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 3.42 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 1.98 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 5.20 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.18 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 4.73 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 3.88 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.00 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.50 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.40 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 2.26 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 1.98 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 3.08 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 3.23 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 1.54 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 2 | 3.47 Ratio |
| Control Ph1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.88 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 1.81 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 4.57 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 1.63 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.58 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 1.77 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 5.44 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 1.87 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 5.10 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 6.44 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 2.02 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 1.94 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 5.98 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 2.30 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 2.82 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.13 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.43 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 2.35 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.05 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 5.42 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.85 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 2.28 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 5.66 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 6.05 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.21 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 5.78 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.33 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 2.35 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 6.05 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A2 Assay 1 | 3.77 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B1 Assay 1 | 3.20 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu A1 Assay 1 | 4.00 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 1 Antibody Titer From Day 1 to Day 92 | Flu B2 Assay 1 | 2.80 Ratio |
Secondary
GMI of Antigen 2 Antibody Titer
Time frame: From Day 1 to Day 92 and Day 1 to Day 183
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 3.05 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.23 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 4.24 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.27 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 3.28 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4.19 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.46 Ratio |
| Flu mRNA_Ph1_7 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.54 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 3.63 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3.10 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 4.90 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 2.36 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 4.31 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.94 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 3.74 Ratio |
| Flu mRNA_Ph1_8 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 4.35 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.35 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.45 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 3.27 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3.15 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.83 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 3.68 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 3.01 Ratio |
| Flu mRNA_Ph1_9 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.56 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.63 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 4.50 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4.10 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 3.58 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 4.64 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.94 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 3.12 Ratio |
| Flu mRNA_Ph1_10 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 4.22 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 3.43 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.36 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.82 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4.08 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.30 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.39 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 4.27 Ratio |
| Flu mRNA_Ph1_11 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 4.04 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 5.31 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 3.48 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.64 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4.98 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 3.25 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.48 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.60 Ratio |
| Flu mRNA_Ph1_12 YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 4.34 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 0.88 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 2.11 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 1.59 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2.48 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 1.45 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 1.23 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.08 Ratio |
| Control Ph1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.21 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.02 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.82 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 2.43 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3.77 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2.80 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 3.41 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.12 Ratio |
| Flu mRNA_Ph2_1_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 4.83 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.15 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.26 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.44 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 3.61 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4.53 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 6.11 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 2.98 Ratio |
| Flu mRNA_Ph2_2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 2.20 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.40 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 6.20 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 3.05 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 4.14 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.39 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.15 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4.62 Ratio |
| Flu mRNA_Ph2_3_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 2.20 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 1.71 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 1.08 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1.54 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.31 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1.33 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 1.13 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 1.12 Ratio |
| Control_Ph2_YA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.59 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2.84 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.18 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.57 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 2.29 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.03 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 3.62 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 4.75 Ratio |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3.73 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.15 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.10 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 3.84 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.00 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3.30 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 2.44 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 4.67 Ratio |
| Flu mRNA_Ph2_2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.63 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2.41 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 2.60 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4.30 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 4.20 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3.28 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 2.45 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.88 Ratio |
| Flu mRNA_Ph2_3_OA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 5.49 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 1.20 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 1.51 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 1.71 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 1.21 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 1.17 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 1.19 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1.85 Ratio |
| Control_Ph2_OA Group | GMI of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1.54 Ratio |
Secondary
GMT of Antigen 1 Antibody Titer
Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: At Day 183
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 290.27 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 121.95 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 12.27 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 124.39 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 159.09 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 517.33 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 40.48 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 118.75 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 20.58 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 154.88 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 444.01 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 100.46 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 28.67 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 165.36 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 451.08 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 98.64 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 498.91 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 142.31 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 134.12 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 20.24 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 146.00 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 96.19 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 449.90 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 39.35 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 23.54 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 95.13 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 413.03 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 161.31 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 104.62 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 666.47 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 34.09 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 208.89 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 489.90 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 166.40 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 100.95 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 31.34 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 448.11 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 81.46 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 29.18 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 196.59 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 29.37 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 70.62 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 163.74 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 461.80 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 81.54 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 25.72 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 428.52 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 171.47 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 12.73 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 210.29 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 791.84 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 114.27 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 40.76 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 315.92 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 350.40 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 25.63 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 349.33 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 30.42 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 46.04 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 416.09 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 45.33 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 34.40 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 338.71 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 424.47 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 468.00 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 403.07 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 24.34 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 30.65 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 291.02 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 58.66 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 30.51 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 453.91 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 66.14 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 328.26 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 425.18 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 38.15 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 469.87 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 65.11 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 340.46 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 40.80 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 28.27 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 44.85 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 397.29 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 557.86 Titers |
Secondary
GMT of Antigen 1 Antibody Titer
Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: At Day 92
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 249.15 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 103.58 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 11.75 Titers |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 219.10 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 181.64 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 502.03 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 55.13 Titers |
| Flu mRNA_Ph1_2 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 192.79 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 166.80 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 141.86 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 29.95 Titers |
| Flu mRNA_Ph1_3 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 383.24 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 190.14 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 467.42 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 54.66 Titers |
| Flu mRNA_Ph1_4 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 170.29 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 180.99 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 537.37 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 205.33 Titers |
| Flu mRNA_Ph1_5 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 29.31 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 159.14 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 161.89 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 463.98 Titers |
| Flu mRNA_Ph1_6 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 60.28 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 155.71 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 162.26 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 405.98 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 39.46 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 181.10 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 544.86 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 44.27 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 200.39 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 486.21 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 187.72 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 189.92 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 43.27 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 40.37 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 441.71 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 186.49 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 178.11 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 139.19 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 55.76 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 204.04 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 446.45 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 442.34 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 184.58 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 36.29 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 157.89 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 175.06 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 722.16 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 2 | 282.65 Titers |
| Control Ph1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 18.15 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 35.51 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 64.25 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 480.70 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 357.44 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 520.76 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 42.16 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 370.02 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 71.59 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 399.21 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 83.99 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 49.93 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 571.84 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 716.31 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 39.61 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 455.96 Titers |
| Control_Ph2_YA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 32.01 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 440.05 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 522.16 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 102.19 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 45.30 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 473.09 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 506.16 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 56.56 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 106.65 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 521.79 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 54.03 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 113.92 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 499.32 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A1 Assay 1 | 37.38 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B2 Assay 1 | 599.30 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu A2 Assay 1 | 71.02 Titers |
| Control_Ph2_OA Group | GMT of Antigen 1 Antibody Titer | Flu B1 Assay 1 | 710.33 Titers |
Secondary
GMT of Antigen 2 Antibody Titer
Time frame: At Day 92 and Day 183
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 482.94 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 3413.56 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1633.79 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 365.32 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 384.20 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1815.84 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 637.45 Titers |
| Flu mRNA_Ph1_7 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3564.38 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 691.16 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 576.79 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 844.82 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 716.17 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 2635.37 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 3012.57 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2310.02 Titers |
| Flu mRNA_Ph1_8 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2569.92 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 2682.13 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 538.10 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 439.50 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 636.20 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1866.83 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 2965.07 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1613.52 Titers |
| Flu mRNA_Ph1_9 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 401.61 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 483.67 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3489.51 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2361.25 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 586.65 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 3738.95 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 696.15 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2262.11 Titers |
| Flu mRNA_Ph1_10 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 593.16 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 784.67 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 3441.57 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 3472.42 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 385.93 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 653.49 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 419.67 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1762.98 Titers |
| Flu mRNA_Ph1_11 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1513.91 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1744.56 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 4239.44 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 844.05 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 661.58 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 438.90 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1909.41 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 4274.50 Titers |
| Flu mRNA_Ph1_12 YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 484.54 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 1169.80 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 411.14 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1298.81 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 302.98 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1187.10 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 261.90 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 1048.36 Titers |
| Control Ph1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 326.16 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 492.09 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 827.90 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1494.07 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 571.40 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 307.31 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1966.97 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 444.85 Titers |
| Flu mRNA_Ph2_1_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 409.51 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 722.85 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 551.37 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 501.61 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1722.00 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 875.59 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 371.76 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 534.28 Titers |
| Flu mRNA_Ph2_2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2217.80 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1688.96 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 734.36 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 512.92 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 585.21 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2214.84 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 545.14 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 1005.14 Titers |
| Flu mRNA_Ph2_3_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 372.01 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 271.70 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 267.02 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1080.66 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 416.04 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 940.94 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 132.78 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 128.40 Titers |
| Control_Ph2_YA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 221.57 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 375.13 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2649.22 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 684.46 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 727.45 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 1202.72 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 532.03 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1923.64 Titers |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 538.58 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 470.78 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 674.07 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2036.73 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 1275.88 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 574.01 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 2803.91 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 388.81 Titers |
| Flu mRNA_Ph2_2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 700.38 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 3061.97 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 1394.04 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 791.40 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 2288.21 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 612.30 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 449.14 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 816.15 Titers |
| Flu mRNA_Ph2_3_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 611.15 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 92 | 355.51 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 183 | 166.23 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A1, Post-dosing at Day 92 | 172.46 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 92 | 566.45 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 183 | 1464.14 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B2, Post-dosing at Day 92 | 1725.34 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu A2, Post-dosing at Day 183 | 397.88 Titers |
| Control_Ph2_OA Group | GMT of Antigen 2 Antibody Titer | Flu B1, Post-dosing at Day 183 | 288.98 Titers |
Secondary
Percentage of Participants With Antigen 1 Antibody SPR
Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.
Time frame: At Day 183
Population: The analysis was performed on the PPS. Only participants with data available for the specified analysis at the specified timepoints were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 94.1 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 88.9 Percentage of participants |
| Flu mRNA_Ph1_1 Younger Adults (YA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 22.2 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 66.7 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 93.3 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_2 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 46.7 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_3 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 86.7 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.0 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_4 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 60.0 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_5 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 47.1 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 56.3 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 81.3 Percentage of participants |
| Flu mRNA_Ph1_6 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 46.7 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 93.3 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_7 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 80.0 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 73.3 Percentage of participants |
| Flu mRNA_Ph1_8 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 50.0 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_9 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 95.0 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 82.4 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_10 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 52.9 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 45.0 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 65.0 Percentage of participants |
| Flu mRNA_Ph1_11 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 77.8 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph1_12 YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 50.0 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 2 | 100 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 33.3 Percentage of participants |
| Control Ph1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 86.7 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 44.2 Percentage of participants |
| Flu mRNA_Ph2_1_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 59.4 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 47.4 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 63.2 Percentage of participants |
| Flu mRNA_Ph2_2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 47.5 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 64.2 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 54.9 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control_Ph2_YA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 37.2 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 67.0 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 99.0 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 39.8 Percentage of participants |
| Flu mRNA_Ph2_1_Older Adults (OA) Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 66.4 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 48.1 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 70.5 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 51.8 Percentage of participants |
| Flu mRNA_Ph2_3_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A1 Assay 1 | 40.7 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B1 Assay 1 | 100 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu B2 Assay 1 | 100 Percentage of participants |
| Control_Ph2_OA Group | Percentage of Participants With Antigen 1 Antibody SPR | Flu A2 Assay 1 | 58.4 Percentage of participants |